Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FASN | P49327 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712143 | 0.95 | HTT (0.75) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL31574444 | 0.90 | HTT (0.83) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL7939852 | 0.87 | FASN (0.70) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL18423 | 0.87 | LMNA (1.00) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL699850 | 0.87 | LMNA (1.00) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL22336666 | 0.84 | LTA4H (0.55) | HTTLMNAMAPTESR1ESR2 | |
| Methane SCHEMBL6378712 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL29056089 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL7929114 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| Fluoride SCHEMBL16505425 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | disclosed |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | NATIONAL INSTITUTES OF HEALTH | 2005-10-27 | — | — | US | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0361119-B1 | Process for the production of benzophenones | BASF AG (DE) | 1993-10-27 | — | — | EP | disclosed |
| EP-0361119-A1 | Process for the production of benzophenones | BASF Aktiengesellschaft (DE) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | PI4KB, HDAC4, PIK3CA | HTT 3125/4885LMNA 1321/4885MAPT 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.